Cardiac Marker Testing Market for Diseases Type (Congestive heart failure and Myocardial infarction) By Testing type (Point-of-care testing and Laboratory testing) By Product Type (Immunofluorescence, Immunochromatography, Instrument, Reagents and kits, Chemiluminescence and Enzyme-linked immunosorbent assay) By Type (C-reactive protein, Troponin I and T, Brain natriuretic peptide or NT-proBNP, CK-MB and Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2026

Description

Cardiac Marker Testing Market: Overview

When the heart is injured or stressed, it releases certain substances into the blood, which function as cardiac markers. The cardiac markers are usually enzymes, proteins, and hormones. Thus, quantification of these biomarkers can aid in diagnosing numerous heart disorders, including cardiac ischemia, acute coronary syndrome, and conditions linked to hindered blood supply to the heart. Physicians usually carry out multiple cardiac marker tests for hours to observe the blood level increase and to recognize the seriousness of a heart attack.

Cardiac Marker Testing Market: Growth Factors

The major factors boosting the growth of global cardiac marker testing include rising expenditure by different institutes to encourage clinical and research studies in biomarker testing, increasing incidence of cardiovascular disorders, and increasing elderly population. However, issues related to storage and collection of samples, compensation, and strict regulatory recommendation are few factors that can hamper the growth of the global market. In addition, estimation of cardiac marker levels in the labs requires considerable time; thus, it cannot be used in the determination of myocardial infarction during the acute phase further restraining its use.

Cardiac Marker Testing Market: Segmentation

The global market for cardiac marker testing can be segmented based on disease, type of testing, product, type, and region. The disease segment of the market is divided into congestive heart failure and myocardial infarction. The type of testing segment of the market is diversified into point-of-care testing and laboratory testing. The product segment of the cardiac marker testing market is classified into immunofluorescence, immunochromatography, instruments, reagents and kits, chemiluminescence, and enzyme-linked immunosorbent assay. The type segment of the market is divided into C-reactive protein, troponin I and T, brain natriuretic peptide or NT-proBNP, CK-MB, other biomarkers, and myoglobin. The other biomarkers segment of the market is classified into H-FABP, homocysteine, myeloperoxidase, galectin-3, and ischemia-modified albumin. Regionally, the cardiac marker testing market is diversified into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Cardiac Marker Testing Market: Regional Analysis

North America is anticipated to dominate the global market of cardiac markers testing. The various factors contributing to the growth of the market in this region include rising aging population, increasing inclination toward point-of-care testing, and elevated frequency of cardiovascular disorders. Asia-Pacific region is also expected to grow in the global market in the near future owing to the huge population, growing incidence of chronic heart diseases, and various measures taken to increase alertness about the diagnosis of cardiac diseases at an early stage.

Cardiac Marker Testing Market: Competitive Players

The key players in the global cardiac marker testing market include Siemens AG, Abbott Laboratories, Danaher Corporation, bioMérieux SA, Alere, Inc., Roche Diagnostics Ltd., Ortho Clinical Diagnostics, LSI Medience Corporation, and Randox laboratories Ltd. The other major players in the global market are Guangzhou Wondfo Biotech Co., Ltd., Bio-Rad Laboratories, Inc., Helomics Corporation, Becton, Dickinson and Company, Avantra Biosciences, and Enzo Biochem.

Cardiac Marker Testing Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table Of Content

• Chapter 1.Preface
  • 1.1.ReportDescription
  • 1.2.Report Scope
• Chapter 2.Research Methodulogy
  • 2.1.Research Methodulogy
  • 2.2.Secondary Research
  • 2.3.Primary Research
  • 2.4.Models
    • 2.4.1.Company Share Analysis Model
    • 2.4.2.Revenue Based Modeling
  • 2.5.Research Limitations
• Chapter 3.Executive Summary
  • 3.1.Global Cardiac Marker TestingMarket, 2016–2026 (USD Million)
  • 3.2.Global Cardiac Marker TestingMarket: Snapshot
• Chapter 4.Cardiac Marker TestingMarket – Industry Analysis
  • 4.1.Introduction
  • 4.2.Market Drivers
    • 4.2.1.Driving Factor 1 Analysis
    • 4.2.2.Driving Factor 2 Analysis:
  • 4.3.Market Restraints
    • 4.3.1.Restraining Factor Analysis
  • 4.4.Market Opportunities
    • 4.4.1.Market Opportunity & Use-case Anaysis
    • 4.4.2.Use – Cases for Cardiac Marker Testing
  • 4.5.Porter’s Five Forces Analysis
  • 4.6.COVID 19 Impact Analysis
    • 4.6.1.1.Impact on Product Development and Technulogy Adoption
    • 4.6.1.2.Gap Analysis

• Chapter 5.Investment Proposition Analysis
  • 5.1.Global Cardiac Marker Testing Market Attractiveness, By Diseases
  • 5.2.Global Cardiac Marker Testing Market Attractiveness, By Testing
  • 5.3.Global Cardiac Marker Testing Market Attractiveness, By Product Type
  • 5.4.Global Cardiac Marker Testing Market Attractiveness, By Type
  • 5.5.Global Cardiac Marker Testing Market Attractiveness, By Region
• Chapter 6.Competitive Landscape
  • 6.1.Company Market Share Analysis - 2019
    • 6.1.1.Global Cardiac Marker Testing Market: Company Market Share, 2019
  • 6.2.Strategic Developments
  • 7.1.Global Cardiac Marker Testing Market Overview: by Diseases
    • 7.1.1.Global Cardiac Marker Testing Market Revenue Share, by Diseases, 2019 & 2026
  • 7.2.Global Cardiac Marker Testing Market Analysis/Overview – By Diseases
    • 7.2.1.Congestive heart failure – Overview/Analysis
    • 7.2.2.Myocardial infarction – Overview/Analysis
  • 7.3.Congestive heart failure
    • 7.3.1.Global Cardiac Marker Testing Market for Congestive heart failure, Revenue (USD Million) 2016 - 2026
  • 7.4.Myocardial infarction
    • 7.4.1.Global Cardiac Marker Testing Market for Myocardial infarction, Revenue (USD Million) 2016 - 2026
  • 8.1.Global Cardiac Marker Testing Market Overview: by Testing
    • 8.1.1.Global Cardiac Marker Testing Market Revenue Share, by Testing, 2019 & 2026
  • 8.2.Global Cardiac Marker Testing Market Analysis/Overview – By Testing
    • 8.2.1.Point-of-care testing – Overview/Analysis
    • 8.2.2.Laboratory testing – Overview/Analysis
  • 8.3.Point-of-care testing
    • 8.3.1.Global Cardiac Marker Testing Market for Point-of-care testing, Revenue (USD Million) 2016 - 2026
  • 8.4.Laboratory testing
    • 8.4.1.Global Cardiac Marker Testing Market for Laboratory testing, Revenue (USD Million) 2016 - 2026
  • 9.1.Global Cardiac Marker Testing Market Overview: by Product Type
    • 9.1.1.Global Cardiac Marker Testing Market Revenue Share, by Product Type, 2019 & 2026
  • 9.2.Global Cardiac Marker Testing Market Analysis/Overview – By Product Type
    • 9.2.1.Immunofluorescence – Overview/Analysis
    • 9.2.2.Immunochromatography – Overview/Analysis
    • 9.2.3.Instrument – Overview/Analysis
    • 9.2.4.Reagents and kits – Overview/Analysis
    • 9.2.5.Chemiluminescence – Overview/Analysis
    • 9.2.6.Enzyme-linked immunosorbent assay – Overview/Analysis
  • 9.3.Immunofluorescence
    • 9.3.1.Global Cardiac Marker Testing Market for Immunofluorescence, Revenue (USD Million) 2016 - 2026
  • 9.4.Immunochromatography
    • 9.4.1.Global Cardiac Marker Testing Market for Immunochromatography, Revenue (USD Million) 2016 - 2026
  • 9.5.Instrument
    • 9.5.1.Global Cardiac Marker Testing Market for Instrument, Revenue (USD Million) 2016 - 2026
  • 9.6.Reagents and kits
    • 9.6.1.Global Cardiac Marker Testing Market for Reagents and kits, Revenue (USD Million) 2016 - 2026
  • 9.7.Chemiluminescence
    • 9.7.1.Global Cardiac Marker Testing Market for Chemiluminescence, Revenue (USD Million) 2016 - 2026
  • 9.8.Enzyme-linked immunosorbent assay
    • 9.8.1.Global Cardiac Marker Testing Market for Enzyme-linked immunosorbent assay, Revenue (USD Million) 2016 - 2026
  • 10.1.Global Cardiac Marker Testing Market Overview: by Type
    • 10.1.1.Global Cardiac Marker Testing Market Revenue Share, by Type, 2019 & 2026
  • 10.2.Global Cardiac Marker Testing Market Analysis/Overview – By Type
    • 10.2.1.C-reactive protein – Overview/Analysis
    • 10.2.2.Troponin I and T – Overview/Analysis
    • 10.2.3.Brain natriuretic peptide or NT-proBNP – Overview/Analysis
    • 10.2.4.CK-MB – Overview/Analysis
    • 10.2.5.Others – Overview/Analysis
  • 10.3.C-reactive protein
    • 10.3.1.Global Cardiac Marker Testing Market for C-reactive protein, Revenue (USD Million) 2016 - 2026
  • 10.4.Troponin I and T
    • 10.4.1.Global Cardiac Marker Testing Market for Troponin I and T, Revenue (USD Million) 2016 - 2026
  • 10.5.Brain natriuretic peptide or NT-proBNP
    • 10.5.1.Global Cardiac Marker Testing Market for Brain natriuretic peptide or NT-proBNP, Revenue (USD Million) 2016 - 2026
  • 10.6.CK-MB
    • 10.6.1.Global Cardiac Marker Testing Market for CK-MB, Revenue (USD Million) 2016 - 2026
  • 10.7.Others
    • 10.7.1.Global Cardiac Marker Testing Market for Others, Revenue (USD Million) 2016 - 2026
• Chapter 11.Cardiac Marker TestingMarket– Regional Analysis
  • 11.1.Global Cardiac Marker TestingMarket: Regional Overview
    • 11.1.1.Global Cardiac Marker Testing Market Revenue Share, by Region, 2019 & 2026
    • 11.1.2.GlobalCardiac Marker Testing Market Revenue, by Region, 2016 – 2026 (USD Million)
  • 11.2.North America
    • 11.2.1.North AmericaCardiac Marker Testing Market Revenue, 2016 - 2026 (USD Million)
    • 11.2.2.North AmericaCardiac Marker Testing Market Revenue, by Country, 2016 – 2026 (USD Million)
    • 11.2.3.North AmericaCardiac Marker Testing Market Revenue, by Diseases, 2016 – 2026
    • 11.2.4.North AmericaCardiac Marker Testing Market Revenue, by Testing, 2016 – 2026
    • 11.2.5.North AmericaCardiac Marker Testing Market Revenue, by Product Type, 2016 – 2026
    • 11.2.6.North AmericaCardiac Marker Testing Market Revenue, by Type, 2016 – 2026
    • 11.2.7. U.S.
    • 11.2.8.Canada
  • 11.3.Europe
    • 11.3.1.EuropeCardiac Marker Testing Market Revenue, 2016 - 2026 (USD Million)
    • 11.3.2.EuropeCardiac Marker Testing Market Revenue, by Country, 2016 – 2026 (USD Million)
    • 11.3.3.EuropeCardiac Marker Testing Market Revenue, by Diseases, 2016 – 2026
    • 11.3.4.EuropeCardiac Marker Testing Market Revenue, by Testing, 2016 – 2026
    • 11.3.5.EuropeCardiac Marker Testing Market Revenue, by Product Type, 2016 – 2026
    • 11.3.6.EuropeCardiac Marker Testing Market Revenue, by Type, 2016 – 2026
    • 11.3.7.Germany
    • 11.3.8.France
    • 11.3.9. U.K.
    • 11.3.10.Italy
    • 11.3.11.Spain
    • 11.3.12.Rest of Europe
  • 11.4.Asia Pacific
    • 11.4.1.Asia PacificCardiac Marker Testing Market Revenue, 2016 - 2026 (USD Million)
    • 11.4.2.Asia PacificCardiac Marker Testing Market Revenue, by Country, 2016 – 2026 (USD Million)
    • 11.4.3.Asia PacificCardiac Marker Testing Market Revenue, by Diseases, 2016 – 2026
    • 11.4.4.Asia PacificCardiac Marker Testing Market Revenue, by Testing, 2016 – 2026
    • 11.4.5.Asia PacificCardiac Marker Testing Market Revenue, by Product Type, 2016 – 2026
    • 11.4.6.Asia PacificCardiac Marker Testing Market Revenue, by Type, 2016 – 2026
    • 11.4.7.China
    • 11.4.8.Japan
    • 11.4.9.India
    • 11.4.10.South Korea
    • 11.4.11.South-East Asia
    • 11.4.12.Rest of Asia Pacific
  • 11.5.Latin America
    • 11.5.1.Latin AmericaCardiac Marker Testing Market Revenue, 2016 - 2026 (USD Million)
    • 11.5.2.Latin AmericaCardiac Marker Testing Market Revenue, by Country, 2016 – 2026 (USD Million)
    • 11.5.3.Latin AmericaCardiac Marker Testing Market Revenue, by Diseases, 2016 – 2026
    • 11.5.4.Latin AmericaCardiac Marker Testing Market Revenue, by Testing, 2016 – 2026
    • 11.5.5.Latin AmericaCardiac Marker Testing Market Revenue, by Product Type, 2016 – 2026
    • 11.5.6.Latin AmericaCardiac Marker Testing Market Revenue, by Type, 2016 – 2026
    • 11.5.7.Brazil
    • 11.5.8.Mexico
    • 11.5.9.Rest of Latin America
  • 11.6.The Middle-East and Africa
    • 11.6.1.The Middle-East and AfricaCardiac Marker Testing Market Revenue, 2016 - 2026 (USD Million)
    • 11.6.2.The Middle-East and AfricaCardiac Marker Testing Market Revenue, by Country, 2016 – 2026 (USD Million)
    • 11.6.3.The Middle-East and AfricaCardiac Marker Testing Market Revenue, by Diseases, 2016 – 2026
    • 11.6.4.The Middle-East and AfricaCardiac Marker Testing Market Revenue, by Testing, 2016 – 2026
    • 11.6.5.The Middle-East and AfricaCardiac Marker Testing Market Revenue, by Product Type, 2016 – 2026
    • 11.6.6.The Middle-East and AfricaCardiac Marker Testing Market Revenue, by Type, 2016 – 2026
    • 11.6.7.GCC Countries
    • 11.6.8.South Africa
    • 11.6.9.Rest of Middle-East Africa
• Chapter 12.Company Profiles
  • 12.1.Siemens AG
    • 12.1.1.Company Overview
    • 12.1.2.Financial Overview
    • 12.1.3.Product Portfulio
    • 12.1.4.Business Strategy
    • 12.1.5.Recent Developments
  • 12.2.Abbott Laboratories
  • 12.3.Danaher Corporation
  • 12.4.bioMérieux SA
  • 12.5.Alere, Inc.
  • 12.6.Roche Diagnostics Ltd.
  • 12.7.Ortho Clinical Diagnostics
  • 12.8.LSI Medience Corporation
  • 12.9.Randox laboratories Ltd
  • 12.1.Guangzhou Wondfo Biotech Co., Ltd.
  • 12.11.Bio-Rad Laboratories, Inc.
  • 12.12.Helomics Corporation
  • 12.13.Becton
  • 12.14.Dickinson and Company
  • 12.15.Avantra Biosciences
  • 12.16.Enzo Biochem
  • 12.17.Others

Methodology